Gilead Sciences, Inc. Scores First Win With Late-Stage Hep C Study

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences (GILD) today announced topline results from the Phase 3 POSITRON study examining a 12-week course of once-daily sofosbuvir plus ribavirin (RBV) i…

---

Novartis AG, AstraZeneca PLC Win EU Drug Okays; Pfizer Inc. Loses Out

Novartis and AstraZeneca won recommendations for important new drugs from European regulators on Friday, while rival Pfizer lost out. The European Medicines Agency said its Committee for Medicinal Pro…

---

Merck & Co., Inc./Ariad Pharmaceuticals, Inc. Fails to Win FDA OK for Sarcoma Drug

WHITEHOUSE STATION, N.J., Jun 05, 2012 (BUSINESS WIRE) -- Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a comple…

---

Johnson & Johnson Fails to Win FDA OK for Daily HIV Pill

Johnson & Johnson said federal drug regulators have not approved its application to market a once-per-day version of its HIV pill Prezista and wants more information. The company said it is review…

---